JP2017501202A5 - - Google Patents

Download PDF

Info

Publication number
JP2017501202A5
JP2017501202A5 JP2016544410A JP2016544410A JP2017501202A5 JP 2017501202 A5 JP2017501202 A5 JP 2017501202A5 JP 2016544410 A JP2016544410 A JP 2016544410A JP 2016544410 A JP2016544410 A JP 2016544410A JP 2017501202 A5 JP2017501202 A5 JP 2017501202A5
Authority
JP
Japan
Prior art keywords
nicotinamide
pyridin
cyano
fluoro
hydroxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016544410A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017501202A (ja
JP6475252B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/010006 external-priority patent/WO2015103453A1/en
Publication of JP2017501202A publication Critical patent/JP2017501202A/ja
Publication of JP2017501202A5 publication Critical patent/JP2017501202A5/ja
Application granted granted Critical
Publication of JP6475252B2 publication Critical patent/JP6475252B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016544410A 2014-01-03 2015-01-02 ヘテロアリール置換のニコチンアミド化合物 Expired - Fee Related JP6475252B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461923403P 2014-01-03 2014-01-03
US61/923,403 2014-01-03
PCT/US2015/010006 WO2015103453A1 (en) 2014-01-03 2015-01-02 Heteroaryl substituted nicotinamide compounds

Publications (3)

Publication Number Publication Date
JP2017501202A JP2017501202A (ja) 2017-01-12
JP2017501202A5 true JP2017501202A5 (enExample) 2018-12-13
JP6475252B2 JP6475252B2 (ja) 2019-02-27

Family

ID=52355270

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016544410A Expired - Fee Related JP6475252B2 (ja) 2014-01-03 2015-01-02 ヘテロアリール置換のニコチンアミド化合物

Country Status (21)

Country Link
US (1) US9169252B2 (enExample)
EP (1) EP3089973B1 (enExample)
JP (1) JP6475252B2 (enExample)
KR (1) KR20160101191A (enExample)
CN (1) CN106061967B (enExample)
AR (1) AR098991A1 (enExample)
AU (1) AU2015204045A1 (enExample)
CA (1) CA2935329A1 (enExample)
CL (1) CL2016001706A1 (enExample)
EA (1) EA201691343A1 (enExample)
ES (1) ES2804707T3 (enExample)
IL (1) IL246474A0 (enExample)
MA (1) MA39162A1 (enExample)
MX (1) MX2016008723A (enExample)
PE (1) PE20161292A1 (enExample)
PH (1) PH12016501164A1 (enExample)
SG (1) SG11201605340QA (enExample)
TN (1) TN2016000271A1 (enExample)
TW (1) TW201609693A (enExample)
UY (1) UY35935A (enExample)
WO (1) WO2015103453A1 (enExample)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2890983A1 (en) 2012-11-08 2014-05-15 Bristol-Myers Squibb Company Heteroaryl substituted pyridyl compounds useful as kinase modulators
JP6215338B2 (ja) 2012-11-08 2017-10-18 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company キナーゼモジュレーターとして有用な二環式ヘテロ環置換ピリジル化合物
GB201311888D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201311891D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compound
CA2935392C (en) 2014-01-01 2022-07-26 Medivation Technologies, Inc. Amino pyridine derivatives for the treatment of conditions associated with excessive tgf.beta activity
US20180228907A1 (en) 2014-04-14 2018-08-16 Arvinas, Inc. Cereblon ligands and bifunctional compounds comprising the same
CN107849039B (zh) 2015-06-24 2020-07-03 百时美施贵宝公司 经杂芳基取代的氨基吡啶化合物
KR102641263B1 (ko) * 2015-06-24 2024-02-26 브리스톨-마이어스 스큅 컴퍼니 헤테로아릴 치환된 아미노피리딘 화합물
TW201713663A (zh) * 2015-06-24 2017-04-16 必治妥美雅史谷比公司 經雜芳基取代之胺基吡啶化合物
GB201518456D0 (en) 2015-10-19 2015-12-02 Galapagos Nv Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory, autoimmune and/or proliferative diseases
WO2017133657A1 (en) * 2016-02-05 2017-08-10 Savira Pharmaceuticals Gmbh Pyridine and pyrimidine derivatives and their use in treatment, amelioration or prevention of influenza
WO2017133667A1 (en) * 2016-02-05 2017-08-10 Savira Pharmaceuticals Gmbh Pyrimidine and pyridine derivatives and use in treatment, amelioration or prevention of influenza thereof
WO2018005863A1 (en) * 2016-07-01 2018-01-04 G1 Therapeutics, Inc. Pyrimidine-based compounds for the treatment of cancer
JOP20180011A1 (ar) * 2017-02-16 2019-01-30 Gilead Sciences Inc مشتقات بيرولو [1، 2-b]بيريدازين
JP7266576B2 (ja) * 2017-08-04 2023-04-28 ブリストル-マイヤーズ スクイブ カンパニー [1,2,4]トリアゾロ[4,3-a]ピリジニル置換のインドール化合物
MX2020002944A (es) 2017-09-14 2020-09-28 Daiichi Sankyo Co Ltd Compuesto que tiene estructura ciclica.
EP4624467A2 (en) 2017-09-22 2025-10-01 Kymera Therapeutics, Inc. Protein degraders and uses thereof
US11358948B2 (en) 2017-09-22 2022-06-14 Kymera Therapeutics, Inc. CRBN ligands and uses thereof
KR20190043437A (ko) 2017-10-18 2019-04-26 씨제이헬스케어 주식회사 단백질 키나제 억제제로서의 헤테로고리 화합물
EP3710443A1 (en) 2017-11-17 2020-09-23 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of interleukin-1 receptor-associated kinase 4 polypeptides
WO2019111218A1 (en) 2017-12-08 2019-06-13 Cadila Healthcare Limited Novel heterocyclic compounds as irak4 inhibitors
TW201927769A (zh) * 2017-12-18 2019-07-16 德商歌林達有限公司 經取代之吡咯啶醯胺ii
IL315310A (en) 2017-12-26 2024-10-01 Kymera Therapeutics Inc Irak degraders and uses thereof
EP3737675A4 (en) 2018-01-12 2022-01-05 Kymera Therapeutics, Inc. Crbn ligands and uses thereof
WO2019140380A1 (en) 2018-01-12 2019-07-18 Kymera Therapeutics, Inc. Protein degraders and uses thereof
CA3090275A1 (en) 2018-02-14 2019-08-22 Dana-Farber Cancer Institute, Inc. Irak degraders and uses thereof
WO2020010177A1 (en) 2018-07-06 2020-01-09 Kymera Therapeutics, Inc. Tricyclic crbn ligands and uses thereof
US12454520B2 (en) 2018-07-06 2025-10-28 Kymera Therapeutics, Inc. Protein degraders and uses thereof
TWI721483B (zh) * 2018-07-13 2021-03-11 美商基利科學股份有限公司 吡咯并[1,2-b]嗒𠯤衍生物
TWI727392B (zh) * 2018-08-13 2021-05-11 美商基利科學股份有限公司 噻二唑irak4抑制劑
KR102195348B1 (ko) 2018-11-15 2020-12-24 에이치케이이노엔 주식회사 단백질 키나제 억제제로서의 신규 화합물 및 이를 포함하는 약제학적 조성물
KR102891608B1 (ko) 2018-11-30 2025-11-28 카이메라 쎄라퓨틱스 인코포레이티드 Irak 분해제 및 이의 용도
ES2983263T3 (es) 2019-08-06 2024-10-22 Bristol Myers Squibb Co Compuestos heterocíclicos bicíclicos útiles como inhibidores de IRAK4
WO2021127283A2 (en) 2019-12-17 2021-06-24 Kymera Therapeutics, Inc. Irak degraders and uses thereof
EP4076520A4 (en) 2019-12-17 2024-03-27 Kymera Therapeutics, Inc. Irak degraders and uses thereof
WO2021158498A1 (en) 2020-02-03 2021-08-12 Bristol-Myers Squibb Company Tricyclic heteroaryl compounds useful as irak4 inhibitors
TW202210483A (zh) 2020-06-03 2022-03-16 美商凱麥拉醫療公司 Irak降解劑之結晶型
CN116867758A (zh) 2020-12-30 2023-10-10 凯麦拉医疗公司 Irak降解剂和其用途
MX2023009527A (es) 2021-02-15 2023-08-24 Kymera Therapeutics Inc Degradadores de la cinasa 4 asociada al receptor de interleucina 1 (irak4) y usos de los mismos.
TW202245789A (zh) 2021-02-15 2022-12-01 美商凱麥拉醫療公司 Irak4降解劑及其用途
AU2022271290A1 (en) 2021-05-07 2023-11-23 Kymera Therapeutics, Inc. Cdk2 degraders and uses thereof
WO2023008973A1 (ko) * 2021-07-29 2023-02-02 프라비바이오 주식회사 신규 벤젠 유도체 및 이의 면역억제 관련 용도
FI4367118T3 (fi) 2021-08-18 2025-04-09 Nurix Therapeutics Inc Interleukiini-1-reseptoriin liittyvien kinaasien bifunktionaalisia hajotusaineita ja niiden terapeuttinen käyttö
IL312397A (en) 2021-10-29 2024-06-01 Kymera Therapeutics Inc IRAK4 subunits and their synthesis
US12091411B2 (en) 2022-01-31 2024-09-17 Kymera Therapeutics, Inc. IRAK degraders and uses thereof
WO2025151602A1 (en) * 2024-01-11 2025-07-17 Bristol-Myers Squibb Company Heteroaryl compounds as ligand directed degraders of irak4
WO2025151728A1 (en) * 2024-01-12 2025-07-17 Bristol-Myers Squibb Company Ligand directed degrader of irak4
CN118388401B (zh) * 2024-06-28 2024-08-20 成都凯斯坦生物医药有限公司 一种4-氨基-2-氯烟醛的制备方法
CN118641677B (zh) * 2024-08-16 2024-11-05 北京京丰制药集团有限公司 尼可刹米原料中杂质的检测方法

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7273868B2 (en) * 2000-04-28 2007-09-25 Tanabe Seiyaku Co., Ltd. Pyrazine derivatives
CA2450769A1 (en) 2001-06-15 2002-12-27 Vertex Pharmaceuticals Incorporated 5-(2-aminopyrimidin-4-yl) benzisoxazoles as protein kinase inhibitors
AUPR688101A0 (en) 2001-08-08 2001-08-30 Luminis Pty Limited Protein domains and their ligands
GB0211019D0 (en) 2002-05-14 2002-06-26 Syngenta Ltd Novel compounds
AU2003244098A1 (en) 2002-06-28 2004-01-19 Yamanouchi Pharmaceutical Co., Ltd. Diaminopyrimidinecarboxa mide derivative
EP1590341B1 (en) 2003-01-17 2009-06-17 Warner-Lambert Company LLC 2-aminopyridine substituted heterocycles as inhibitors of cellular proliferation
JP2007523867A (ja) 2003-07-10 2007-08-23 ニューロジェン・コーポレーション 置換複素環式ジアリールアミン類縁体
GB0402653D0 (en) 2004-02-06 2004-03-10 Cyclacel Ltd Compounds
US7521457B2 (en) 2004-08-20 2009-04-21 Boehringer Ingelheim International Gmbh Pyrimidines as PLK inhibitors
FR2896503B1 (fr) 2006-01-23 2012-07-13 Aventis Pharma Sa Nouveaux derives soufres d'uree cyclique, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases
AU2008258508A1 (en) 2007-06-08 2008-12-11 Bayer Cropscience Ag Fungicide heterocyclyl-pyrimidinyl-amino derivatives
WO2009046416A1 (en) 2007-10-05 2009-04-09 Targegen Inc. Anilinopyrimidines as jak kinase inhibitors
KR101361027B1 (ko) * 2008-11-28 2014-02-11 코와 가부시키가이샤 피리딘-3-카르복시아미드 유도체
WO2010144647A1 (en) * 2009-06-12 2010-12-16 Bristol-Myers Squibb Company Nicotinamide compounds useful as kinase modulators
CA2778979C (en) 2009-10-30 2018-04-24 Janssen Pharmaceutica Nv Phenoxy-substituted pyrimidines as opioid receptor modulators
CN102971304A (zh) 2010-02-01 2013-03-13 日本化学医药株式会社 Gpr119激动剂
JP2014515029A (ja) 2011-04-29 2014-06-26 アイカーン・スクール・オブ・メディシン・アト・マウント・シナイ キナーゼ阻害剤
US9074384B2 (en) * 2011-07-27 2015-07-07 Intex Recreation Corp. Combined swimming pool ladder structure
WO2013106641A1 (en) 2012-01-13 2013-07-18 Bristol-Myers Squibb Company Thiazolyl- or thiadiazolyl-substituted pyridyl compounds useful as kinase inhibitors
CN104169275B (zh) 2012-01-13 2017-06-09 百时美施贵宝公司 用作激酶抑制剂的三唑取代的吡啶化合物
JP6109195B2 (ja) * 2012-01-13 2017-04-05 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company キナーゼ阻害剤として有用な複素環置換されたピリジル化合物
CA2890983A1 (en) * 2012-11-08 2014-05-15 Bristol-Myers Squibb Company Heteroaryl substituted pyridyl compounds useful as kinase modulators
AR093403A1 (es) 2012-11-08 2015-06-03 Bristol Myers Squibb Co COMPUESTOS DE PIRIDILO SUSTITUIDOS CON ALQUILAMIDA UTILES COMO MODULADORES DE LAS RESPUESTAS DE IL-12, IL23 Y/O INFa
JP6215338B2 (ja) * 2012-11-08 2017-10-18 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company キナーゼモジュレーターとして有用な二環式ヘテロ環置換ピリジル化合物

Similar Documents

Publication Publication Date Title
JP2017501202A5 (enExample)
JP6475252B2 (ja) ヘテロアリール置換のニコチンアミド化合物
JP2018522859A5 (enExample)
JP7576552B2 (ja) イミダゾ[1,2-a]ピリジニル誘導体及び疾患の処置におけるその使用
EP2558468B1 (en) 5, 7-substituted-imidazo [1,2-c] pyrimidines as inhibitors of jak kinases
KR102319857B1 (ko) P2x7 조절제
RU2473549C2 (ru) Пиримидиновые соединения, композиции и способы применения
JP6689871B2 (ja) Fgfr阻害剤としての二環式複素環
AU2018353759B2 (en) Heterocyclic compound as a protein kinase inhibitor
JP2020164537A (ja) Syk阻害剤としての縮合複素芳香族ピロリジノン
AU2017378943A1 (en) FGFR4 inhibitor, preparation method therefor and pharmaceutical use thereof
JP2016523911A5 (enExample)
AU2010335556A1 (en) Imidazopyridine derivatives as JAK inhibitors
TW201326173A (zh) 5,7-經取代之-咪唑并[1,2-c]嘧啶
JP2018524331A5 (enExample)
JP2015527399A5 (enExample)
JP2013523884A5 (enExample)
JP2023510874A (ja) 置換ピラゾロ-ピリミジンおよびその使用
US9150592B2 (en) Heterocyclic nuclear hormone receptor modulators
JPWO2021021986A5 (enExample)
CN107108653B (zh) 吡唑并噻唑化合物及医药
TW202412783A (zh) 酪胺酸激酶2抑制劑及其用途
JPWO2021030379A5 (enExample)
TW202415666A (zh) 新穎雜環化合物
WO2025017078A1 (en) New pyrazolopyridine derivatives